#1 Clinical Trials Search in Europe

Tocilizumab

Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has shown promising results in clinical trials for treating various conditions. This article explores the use of tocilizumab in clinical trials for diseases such as COVID-19, neuromyelitis optica spectrum disorders (NMOSD), rheumatoid arthritis, and lung transplantation. We’ll discuss its potential benefits, dosing strategies, and safety considerations across different patient populations.

Table of Contents

What is Tocilizumab?

Tocilizumab is a medication used to treat various inflammatory conditions. It’s also known by the brand names RoActemra and Actemra[1]. Tocilizumab is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that mimics the immune system’s ability to fight off harmful pathogens such as viruses[2].

What Conditions Does Tocilizumab Treat?

Tocilizumab is used to treat several conditions, including:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting the joints[3].
  • COVID-19: Severe cases of COVID-19 associated with a cytokine storm (an overreaction of the immune system)[4].
  • Takayasu Arteritis: A rare type of blood vessel inflammation[5].
  • Fibrous Dysplasia of Bone: A bone disorder that causes abnormal growth patterns and fragile bones[6].

How Does Tocilizumab Work?

Tocilizumab works by blocking a protein in the body called interleukin-6 (IL-6). IL-6 is involved in causing inflammation in the body. By blocking IL-6, tocilizumab helps to reduce inflammation and relieve symptoms in various conditions[2].

In the case of COVID-19, tocilizumab is used to combat the “cytokine storm,” which is an overreaction of the immune system that can cause severe inflammation and damage to the lungs and other organs[4].

How is Tocilizumab Administered?

Tocilizumab can be administered in two main ways:

  1. Intravenous (IV) infusion: The medication is given directly into a vein. For example, in some COVID-19 studies, patients received 8 mg/kg of tocilizumab intravenously[4].
  2. Subcutaneous injection: The medication is injected under the skin. In some rheumatoid arthritis studies, patients received 162 mg of tocilizumab subcutaneously once a week[3].

The dosage and frequency of administration can vary depending on the condition being treated and the individual patient’s needs.

Effectiveness of Tocilizumab

The effectiveness of tocilizumab has been studied in various conditions:

  • Rheumatoid Arthritis: Studies have shown that tocilizumab can help reduce disease activity and improve physical function in patients with RA[7].
  • COVID-19: Some studies have suggested that tocilizumab may help reduce mortality and the need for mechanical ventilation in severe COVID-19 cases[4].
  • Takayasu Arteritis: Research has indicated that tocilizumab may be effective as a first-line treatment for inducing remission in this condition[5].

Potential Side Effects

Like all medications, tocilizumab can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Headache
  • High blood pressure
  • Abnormal liver function tests
  • Allergic reactions

It’s important to discuss potential side effects with your healthcare provider before starting treatment[7].

Ongoing Research and Future Prospects

Research on tocilizumab is ongoing, with several clinical trials investigating its use in various conditions:

  • Its effectiveness in early, moderate to severe rheumatoid arthritis[8].
  • Its potential in treating cytokine release syndrome associated with COVID-19[9].
  • Its use in fibrous dysplasia of bone for patients who don’t respond to other treatments[6].

These ongoing studies may lead to new applications for tocilizumab in the future, potentially benefiting more patients with inflammatory conditions.

Condition Dosage Key Outcomes Measured Potential Benefits
COVID-19 Pneumonia 4-8 mg/kg IV Mortality rate, time to recovery, CRP levels Reduced inflammation, improved respiratory function
Neuromyelitis Optica Spectrum Disorders (NMOSD) 8 mg/kg IV every 4-6 weeks Relapse rate, disability progression, visual function Reduced relapse frequency, improved neurological function
Rheumatoid Arthritis 162 mg SC weekly or every 2 weeks Disease activity scores, drug levels Optimized dosing, reduced disease activity
Lung Transplantation Not specified CLAD development, re-transplantation rates, survival Reduced inflammation, improved graft survival

FAQ

  • What is tocilizumab and how does it work? Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor. It works by blocking the IL-6 signaling pathway, which plays a role in inflammation and immune responses. By inhibiting this pathway, tocilizumab can help reduce inflammation and symptoms in various conditions.
  • In which conditions is tocilizumab being studied? Tocilizumab is being studied in clinical trials for several conditions, including COVID-19 pneumonia, neuromyelitis optica spectrum disorders (NMOSD), rheumatoid arthritis, and in lung transplant recipients. It shows potential in reducing inflammation and improving outcomes in these diverse conditions.
  • What are the potential benefits of tocilizumab in COVID-19 treatment? In COVID-19 clinical trials, tocilizumab is being studied for its potential to reduce inflammation, improve respiratory function, and decrease mortality rates in patients with severe COVID-19 pneumonia. Some studies are exploring its effectiveness in preventing the need for invasive mechanical ventilation and reducing hospital length of stay.
  • How is tocilizumab administered in clinical trials? The administration of tocilizumab varies depending on the condition and specific trial. In most studies, it is given intravenously (IV) at doses ranging from 4 mg/kg to 8 mg/kg. Some trials are exploring lower doses or different dosing intervals to optimize treatment while minimizing side effects.
  • What are the potential side effects of tocilizumab? Common side effects of tocilizumab may include infections, gastrointestinal perforations, and changes in liver function tests. Clinical trials are closely monitoring for adverse events, including serious infections, malignancies, and tuberculosis. The safety profile is being evaluated in different patient populations to determine the best use of the drug.

Ongoing Clinical Trials on Tocilizumab

  • Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany

  • A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain Sweden

  • A study comparing AZD0486 after reduced chemotherapy versus standard chemotherapy in older or unfit patients with newly diagnosed large B-cell lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy The Netherlands Spain

  • A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium France Ireland Italy Poland Spain

  • Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren’s Disease

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Hungary Italy Spain

  • Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +11

  • Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Safety and Effectiveness of ARI0002h and Drug Combination for Newly Diagnosed Primary Plasma Cell Leukemia Patients

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

Glossary

  • Tocilizumab: A humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, used to treat various inflammatory conditions.
  • Interleukin-6 (IL-6): A protein produced by the body that plays a role in immune responses and inflammation.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body, such as on the surface of cells.
  • COVID-19 pneumonia: Inflammation of the lungs caused by the SARS-CoV-2 virus, which can lead to severe respiratory problems.
  • Neuromyelitis optica spectrum disorders (NMOSD): A group of rare autoimmune conditions that primarily affect the optic nerves and spinal cord.
  • Rheumatoid arthritis: A chronic inflammatory disorder that primarily affects the small joints of the hands and feet.
  • Lung transplantation: A surgical procedure to replace a diseased or failing lung with a healthy lung from a donor.
  • C-reactive protein (CRP): A protein produced by the liver in response to inflammation, often used as a marker of inflammation in the body.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Chronic Lung Allograft Dysfunction (CLAD): A form of chronic rejection that can occur after lung transplantation, leading to declining lung function.

References

  1. https://clinicaltrials.gov/study/NCT02552940
  2. https://clinicaltrials.gov/study/NCT04331808
  3. https://clinicaltrials.gov/study/NCT02011334
  4. https://clinicaltrials.gov/study/NCT04730323
  5. https://clinicaltrials.gov/study/NCT02101333
  6. https://clinicaltrials.gov/study/NCT01791842
  7. https://clinicaltrials.gov/study/NCT01649804
  8. https://clinicaltrials.gov/study/NCT01730456
  9. https://clinicaltrials.gov/study/NCT04424056